Diffuse Large B-Cell Lymphoma

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in the position.

SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival outcomes than those who received the agents in pivotal trials.

SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Paolo Caimi, MD, spoke with Healio about the latest results from the POLARIX trial presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Paolo Caimi, MD, spoke with Healio about research updates on chimeric antigen receptor T-cell therapy presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A rapidly delivered tandem chimeric antigen receptor T-cell therapy produced favorable outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma, according to interim results of a phase 2 trial.

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more previous lines of therapy.

A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.

CHICAGO — Treatment of with an investigational chimeric antigen receptor T-cell therapy showed an acceptable safety profile and produced durable remissions among certain patients with non-Hodgin lymphoma.

The addition of glofitamab-gxbm to gemcitabine and oxaliplatin improved OS among patients with relapsed or refractory diffuse large B-cell lymphoma compared with rituximab, gemcitabine and oxaliplatin, according to the agent’s manufacturer.